Difference between revisions of "Cytarabine (Ara-C)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Peripheral T-cell lymphoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 24: | Line 27: | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
| − | |||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[T-cell acute lymphoblastic leukemia]] | *[[T-cell acute lymphoblastic leukemia]] | ||
Revision as of 00:43, 20 May 2022
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2]
Route: IV, IT, SC
Extravasation: irritant or neutral, depending on reference
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- Burkitt lymphoma
- B-cell acute lymphoblastic leukemia
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hypereosinophilic syndrome
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Myelodysplastic syndrome
- Primary mediastinal B-cell lymphoma
- T-cell acute lymphoblastic leukemia
- Transformed lymphoma
Diseases for which it was used
Patient drug information
- Cytarabine (Cytosar) package insert[1]
- Cytarabine (Cytosar) patient drug information (Chemocare)[3]
- Cytarabine (Cytosar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/17/1969: initial FDA approval
- 10/15/1998: (earliest label available on Drugs@FDA) indicated in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration is indicated in the prophylaxis and treatment of meningeal leukemia.
Also known as
- Generic names: Ara-C, arabinosylcytosine, arabinofuranosyl cytidine, cytosine arabinoside
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alcysten | Alexan | ARA | Arabine | Arabitin | Aracitin | Aracytin | Aracytine |
| Citagenin | Citaloxan | Citarabin | Citarabina | Citarabins | Citarax | Cylocide | Cytarabin |
| Cytarabins | Cytarabinum | Cytarbel | Cytarine | Cytosar | Cytosar-U | Cytrosar | Depocyt |
| Depocyte | Erbabin | Erpalfa | Fauldcita | Groven | Ifarab | Iretin | Laracit |
| Medsara | Novutrax | Remcyta | Starasid | Tabin | Tabine | Udicil | |
References
Categories:
- Drugs
- Intrathecal medications
- Intravenous medications
- Subcutaneous medications
- Irritant
- Neutral
- Antimetabolites
- Deoxycytidine analogues
- B-cell acute lymphoblastic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- Burkitt lymphoma medications
- Chronic lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hypereosinophilic syndrome medications
- Langerhans cell histiocytosis medications
- Mantle cell lymphoma medications
- Myelodysplastic syndrome medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- T-cell acute lymphoblastic leukemia medications
- Transformed lymphoma medications
- Multiple myeloma medications (historic)
- FDA approved in 1969
- WHO Essential Cancer Medicine